FDA Requires Rare Vision-Loss Warning on GLP-1 Diabetes and Weight-Loss Medicines

The US Food and Drug Administration (FDA) is requiring all GLP-1 receptor agonists, a class of medicines used to treat type 2 diabetes or to reduce excess body weight, to add information about a rare eye risk to the warnings section of their official labeling. The FDA issued the requirement in a Drug Safety Communication, a public notice about medicine safety, dated November 9, 2026.

The risk concerns a condition called NAION. It is a sudden reduction of blood flow to the optic nerve, the nerve that carries vision from the eye. NAION causes acute, painless loss of vision in one eye, and that loss can be permanent.

The FDA concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 medicines. According to The Guardian, the agency reviewed 126 clinical trials involving more than 134,200 patients. It identified 15 probable NAION cases: 10 among patients taking GLP-1 medicines, 5 among patients given a placebo (an inactive treatment), and none among patients taking other glucose-lowering medicines that are not GLP-1 drugs.

The FDA put the rate among GLP-1 patients at 6.4 cases per 100,000 person-years, a measure that accounts for how long participants were observed. Among patients on placebo or other glucose-lowering medicines, the rate was 3.8 cases, according to the same reporting.

The requirement covers Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro and Zepbound, and Sanofi's Soliqua, The Guardian reported. Novo Nordisk said it continues to believe the data do not establish a cause-and-effect relationship between its medicines and NAION. The company also said it remains confident in the benefit-risk profile of its GLP-1 medicines.

The FDA describes the typical symptoms as sudden, painless vision loss in one eye, which a patient may first notice upon waking. Other symptoms include blurred or missing areas of vision, distorted colors, and reduced sharpness in the center of vision. The agency lists smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease as possible risk factors.

If NAION has occurred in one eye, the FDA states that there is an increased risk it will occur in the other eye.